glp-1 insulin Schematic pathway showing release of by GLP-1. Binding of Glucagon-like peptide-1 (GLP-1) receptor agonists

Diabetes & Endocrinology

385,387 PF1801 displays its anti-inflammatory effects by lowering levels of inflammatory mediators such as TNF, IL-6, and HMGB1, and enhances the cells antioxidant capability by upregulating molecules like Nfe2l2, Hmox1, Gclm, and Nqo1, which further improves cellular defense against oxidative stress and protects them from further damage

El mecanismo de accin de los agonistas GLP-1 es multifactico

They found that GLP-1 users had a 37% higher risk of alopecia than those taking SGLT-2 inhibitors, and a 68% higher risk compared with those using DPP-4 inhibitors

doi: 10.3233/JAD-190237 142 ParthsarathyVHolscherC